KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $8.9 million.

  • AbCellera Biologics' Capital Expenditures fell 5178.22% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 3709.73%. This contributed to the annual value of $78.4 million for FY2024, which is 188.31% up from last year.
  • Per AbCellera Biologics' latest filing, its Capital Expenditures stood at $8.9 million for Q3 2025, which was down 5178.22% from $13.4 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Capital Expenditures peaked at $36.8 million during Q2 2021, and registered a low of $3.6 million during Q1 2021.
  • Over the past 5 years, AbCellera Biologics' median Capital Expenditures value was $14.5 million (recorded in 2022), while the average stood at $16.7 million.
  • As far as peak fluctuations go, AbCellera Biologics' Capital Expenditures skyrocketed by 89389.68% in 2021, and later plummeted by 5594.03% in 2025.
  • Quarter analysis of 5 years shows AbCellera Biologics' Capital Expenditures stood at $9.4 million in 2021, then surged by 30.75% to $12.3 million in 2022, then grew by 17.04% to $14.4 million in 2023, then grew by 8.31% to $15.6 million in 2024, then plummeted by 42.88% to $8.9 million in 2025.
  • Its Capital Expenditures was $8.9 million in Q3 2025, compared to $13.4 million in Q2 2025 and $10.6 million in Q1 2025.